Drugs / CELLISTEM-OA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03810521 | Mar → Oct 2019 | osteoarthritis, knee | Universidad de los Andes, Chile | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04863183 | Jun → Dec 2021 | osteoarthritis, knee | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CELLISTEM-OA | “Dose-escalation of Cellistem-OA in Patients With Knee Osteoarthritis” NCT03810521 ↗ |
| Modality | Cell therapy | “biological therapy based on mesenchymal stem cells” NCT04863183 ↗ |
| Route | Other | “CELLISTEM-OA via intra-articular, doses of 2 x 106 mesenchymal stem cells in 5cc of saline solution.” NCT04863183 ↗ |